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tection rate. In a previous work we have described a procedure allowing an extensive
re-sequencing (by cycle sequencing, Applied Biosystems) of all exons and of the ad-
jacent intronic zones of CFTR (30 amplicons, each subjected to forward and reverse
sequencing), that can ﬁt in a 8× 12 (= 96-well) format, with simultaneous exami-
nation of 11 subjects (plus one blank). We are presenting here an almost fully auto-
mated version of this method, based on the combined use of a Hamilton 4-channels
StarLet robotics system and an Applied Biosystems ABI PRISM 3100 Avant genetic
analyzer (4-capillaries), with an analysis of time and costs of this automated proce-
dure and an assessment of its advantages. The CFTR complete scan of 11 subjects
actually starts the ﬁrst day with the assembly of the ﬁrst plate, followed by 13 days of
ABI PRISM time (in the meantime, all plates could be prepared and run one after the
other). By using our personalized CFTR-template, the large set of sequencing data
produced is easily processed by SeqScape software for sequence analysis (Applied
BioSystems). One additional day is then needed for software analysis of the last
plate. The limiting step in this process is the development of the electropherograms
by the 4-capillaries genetic analyzer, since approximately 80 hours are required for
a full analysis of 96 samples (forward and reverse, run in duplicate). A different
hardware conﬁguration (16-channels, instead of 4, for both instruments) markedly
reduces the overall time to 5 days, 3 of which of ABI PRISM time. The overall
cost for a complete CFTR scan by this automated method, including consumables
(tips, plates, capillary arrays) and reagents (Taq polymerase, POP-6 polymer and
BigDye terminators), is about 240 euros/subject. A very limited human involvement
is needed after robotics programming. The overall costs of this procedure, especially
if its high detection rate is taken into account, are comparable to those of other
scanning techniques and also of methods focused on limited number of mutations.
For a high productivity, the use of a 16-analytical channel instrument is advised.
S. P. was partially supported by a grant from “Associazione Laziale Fibrosi Cistica”.
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Although there are more than 1000 mutations in the cystic ﬁbrosis transmembrane
conductance regulator (CFTR) gene, most of them are uncommon and only limited
informations exist regarding genotype–phenotype correlation. In this survey we
retrospectively examined our screened population of CF patients, diagnosed from
July 2000 to May 2007, in order to investigate the relationship between their clinical
status and genotype.
Patients were classiﬁed depending on the CFTR mutation class on each chromo-
some. They were subsequently categorized into two groups according to whether the
CFTR protein reached the epithelial surface (Group 2: at least one mutation class
type III-IV-V) or not (Group 1: type I or II mutation class on both chromosome).
We considered age, sex, neonatal screening results, sweat test values, pancreatic
sufﬁciency and Pseudomonas aeruginosa ﬁrst infection.
From July 2000 to May 2007 we diagnosed 73 patients (40 females and 23 males)
for whom it was possible to identify both CFTR mutations; they actually have a
mean age of 3.92 years. We identiﬁed in Group 1 52 patients (27 M and 25 F)
with a mean age of 3.75 years and in Group 2 21 patients (6M and 15 F) with a
mean age of 4.3 years. Six patients of Group 1 (8.6%) vs 3 patients (7%) of Group
2 resulted as false negative at the neonatal screening. The mean sweat test value
was 100.17 mEq/l (IC 95% range 86.28–114.06) for the ﬁrst group of patients and
84.41 mEq/L (IC 95% range 67.93–100.89) for the second group with p: 0.18.
With regard to the pancreatic status 35 patients out of 52 (67.3%) in Group 1 have
pancreatic insufﬁciency vs 2 patients out of 21 (9.5%) in Group 2 (p< 0.05). Thirty-
three patients of our population have had ﬁrst Pseudomonas aeruginosa infection:
27/52(51.9%) in Group 1 of patients and 6/21 (28.5%) in Group 2. The mean age
of acquisition was for Group 1 1.12 years vs 1.36 years for Group 2 (p: 0.6), but the
patients who are actually negative for Pseudomonas aeruginosa infection are 25/52
in the ﬁrst group with a mean age of 2.8 years and 15/21 in the second group with
a mean age of 4.01 years (p: 0.08).
Conclusions: screening diagnosed patients belonging to ﬁrst and second class
mutation genotype present an earlier Pseudomonas aeruginosa infection in respect
of patients group having other mutations (class type III-IV-V).
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Neonatal screening for CF has been introduced in July 2000 as investigational
procedure in Piedmont Region (Italy). Until May 2007 96 children have been
diagnosed at our CF Center: 19 patients out of 96 resulted false negative at
the neonatal screening and therefore were diagnosed by symptoms. The genetic
diagnosis is performed at ﬁrst instance by the analysis of the 31 most common
mutations using the OLA-PCR-SCS method and then, if necessary, by the whole
gene scan with DHPLC method. In 45 patients out of 96 it has been necessary
to apply DHPLC: in 15 patients out 45 the neonatal screening has resulted false
negative. Using DHPLC both mutations were detected in 30 out of 45 patients;
in 15 cases only one mutation (13 cases) or no mutation (2 cases) were found: 7
patients of this group had been false negative at neonatal screening.
Mutations detected by DHPLC belong to mutation class I in 45.83% of cases, to
class IV in 16.67% and to class III in 4.17% of cases. The table shows the class
of mutation detected in our population with OLA and DHPLC.
Mutation class Frequency Percentage Cumulative percentage
II 111 58.73 58.73
I 30 15.87 74.60
N 24 12.70 87.30
IV 17 8.99 96.30
V 5 2.65 98.94
III 2 1.06 100.00
Total 189 100.0
Conclusions: neonatal screening has permitted to modify patient’s population,
detecting also uncommon mutations; furthermore neonatal screening seems to be
more sensitive for patients with mutation class I or II.
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Background: Mutations in the Cystic Fibrosis Transmembrane Conductance Reg-
ulator (CFTR) gene cause Cystic Fibrosis (CF). They are also involved in other
diseases, such as idiopathic pancreatitis.
Case-report: We present a case-report of a family composed by four per-
sons in which genetic analysis showed an identical homozygous genotype
(D1152H/D1152H) in the mother and her two sons, associated with different clinical
expressions. In fact, only the second born male had a pathological sweat test and a
diagnosis of a mild form of classic CF, with a minimal lung disease and pancreatic
sufﬁciency. On the other hand, the mother and the ﬁrst born female had an exclusive
pancreatic involvement and signs of chronic pancreatitis: the mother had only one
clinical expression in her life referable to an acute pancreatitis, whereas her daughter
was affected by recurrent episodes of pancreatitis conﬁned to her ﬁrst years of life.
Both patients showed normal chloride values at the sweat test.
Conclusions: This report conﬁrms the difﬁculties for diagnosing atypical CF
and emphasizes the role of CFTR mutations in the pathogenesis of idiopathic
pancreatitis. In particular, D1152H mutation is strictly associated with atypical
expression of CF and pancreatic sufﬁciency. The phenotypic variability seen in this
family could be determined by other non-CFTR genes acting as possible modiﬁers
of disease expression; alternatively, gender differences may be involved in the
determination of CF phenotype, as suggested by several observations in literature.
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Background: Non-classic Cystic Fibrosis (CF) currently represents a difﬁcult entity
to deﬁne for clinicians, especially at the early stage of the disease, because of
unusual presentation and/or late onset of symptoms. Moreover, the sweat test may
show border-line or normal values and the diagnosis is mainly based on clinical
features and follow-up. Genetic analysis of the Cystic Fibrosis Transmembrane
Conductance Regulator (CFTR) gene may identify one severe or mild mutation in
